Hormonal Contraception — Competitive Intelligence Brief

Hormonal Contraception (Hormonal Contraception) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hormonal contraceptive. Area: Reproductive Health / Contraception.

phase 3 Hormonal contraceptive Estrogen receptor, Progesterone receptor Reproductive Health / Contraception Small molecule

Target snapshot

Hormonal Contraception (Hormonal Contraception) — University of Alabama at Birmingham. Hormonal contraception prevents pregnancy by suppressing ovulation through synthetic hormones that inhibit the luteinizing hormone (LH) surge.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hormonal Contraception TARGET	Hormonal Contraception	University of Alabama at Birmingham	phase 3	Hormonal contraceptive	Estrogen receptor, Progesterone receptor
Ethinyl Estradiol + Desogestrel	Ethinyl Estradiol + Desogestrel	Massachusetts General Hospital	marketed	Combined oral contraceptive	Estrogen receptor, progesterone receptor
Ethinylestradiol / Dienogest	Ethinylestradiol / Dienogest	University of Palermo	marketed	Combined oral contraceptive	Estrogen receptor, progesterone receptor
oral contraceptives	oral contraceptives	FHI 360	marketed	Hormonal contraceptive	Estrogen receptor, Progesterone receptor
Tibolone (Livial)	Tibolone (Livial)	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Selective tissue estrogenic activity regulator (STEAR); synthetic steroid	Estrogen receptor, progesterone receptor, androgen receptor
ethinyl estradiol and cyproterone acetate	ethinyl estradiol and cyproterone acetate	S.C.B. Medical College and Hospital	marketed	Combined oral contraceptive with anti-androgenic activity	Estrogen receptor, progesterone receptor, androgen receptor
fenofibrate and tibolone	fenofibrate and tibolone	Keogh Institute for Medical Research	marketed	Fibrate + Selective Estrogen Receptor Modulator (SERM)	PPAR-α (fenofibrate); Estrogen receptor, progesterone receptor, androgen receptor (tibolone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hormonal contraceptive class)

1. Penn State University · 2 drugs in this class
2. Italfarmaco · 1 drug in this class
3. Kayseri Education and Research Hospital · 1 drug in this class
4. TherapeuticsMD · 1 drug in this class
5. University of Alabama at Birmingham · 1 drug in this class
6. University of Athens · 1 drug in this class
7. FHI 360 · 1 drug in this class
8. University of Pittsburgh · 1 drug in this class